OCUTF (Ocumension Therapeutics) ROC (Joel Greenblatt) %: -8.07% (As of Dec. 2025)


OCUTF Ocumension Therapeutics OCUTF
52 GF Score
Price $0.70
GF Value $2.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ocumension Therapeutics ROC (Joel Greenblatt) %?

Ocumension Therapeutics OCUTF 52 ROC (Joel Greenblatt) % is -8.07% as of Dec. 2025. GuruFocus rates OCUTF with a GF Score™ of 52/100 and a GF Value™ of $2.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,329 Biotechnology companies, Ocumension Therapeutics ranks better than 71.03% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Ocumension Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -8.07%.

The historical rank and industry rank for Ocumension Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

OCUTF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -77298.74   Med: -105.42   Max: -26.77
Current: -26.77

During the past 8 years, Ocumension Therapeutics's highest ROC (Joel Greenblatt) % was -26.77%. The lowest was -77298.74%. And the median was -105.42%.

OCUTF's ROC (Joel Greenblatt) % is ranked better than
71.03% of 1329 companies
in the Biotechnology industry
Industry Median: -298.7 vs OCUTF: -26.77

Ocumension Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 56.40% per year.


Ocumension Therapeutics  (OTCPK:OCUTF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Ocumension Therapeutics ROC (Joel Greenblatt) % Related Terms


Ocumension Therapeutics ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Ocumension Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics ROC (Joel Greenblatt) % Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -116.40 -94.38 -81.63 -53.45 -26.81

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.79 -61.92 -46.07 -48.44 -8.07

OCUTF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Ocumension Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocumension Therapeutics ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's ROC (Joel Greenblatt) % falls into.


OCUTF
52GF Score
Ocumension Therapeutics OCUTF
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocumension Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(24.093 + 9.249 + 0) - (7.955 + 0 + 10.47)
=14.917

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(48.219 + 9.075 + 0) - (14.905 + 0 + 12.692)
=29.697

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Ocumension Therapeutics for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.048/( ( (65.234 + max(14.917, 0)) + (64.829 + max(29.697, 0)) )/ 2 )
=-7.048/( ( 80.151 + 94.526 )/ 2 )
=-7.048/87.3385
=-8.07 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -8.07% mean?
Ocumension Therapeutics (OCUTF) has a ROC (Joel Greenblatt) % of -8.07% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Ocumension Therapeutics and its competitors. According to the industry distribution chart, Ocumension Therapeutics ranks #385 out of 1329 companies in the Biotechnology industry, placing it in the top 29%.
Is Ocumension Therapeutics' ROC (Joel Greenblatt) % too high?
Ocumension Therapeutics' current ROC (Joel Greenblatt) % is -8.07%. Based on the distribution chart, Ocumension Therapeutics ranks #385 out of 1329 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocumension Therapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #385 out of 1329 companies for ROC (Joel Greenblatt) %. This puts Ocumension Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Ocumension Therapeutics and its competitors. Ocumension Therapeutics's current ROC (Joel Greenblatt) % is -8.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.82, compared to a current price of $0.70 — trading 75.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is -8.07%. Ocumension Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current ROC (Joel Greenblatt) % is -8.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?

Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued. The current stock price of $0.70 is trading 75.2% below its estimated GF Value™ of $2.82. GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.

Key valuation signals for OCUTF:

  • ROC (Joel Greenblatt) %: -8.07%
  • GF Value™: $2.82 vs. price of $0.70 (75.2% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocumension Therapeutics Business Description

Other Exchanges 01477:Hong Kong5DG:Germany
Address No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score

Get the complete analysis for OCUTF

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$2.82
GF Value